Peply
← All Compounds

Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

Dihexa Acetate

Removed from Cat 2

Neuropeptide · Research peptide (multiple suppliers)

Synthetic angiotensin IV-derived oligopeptide investigated as an HGF/c-Met activator with reported synaptogenic and procognitive activity in preclinical studies. Not FDA-approved for any indication.

About

Mechanism
Synthetic oligopeptide derived from angiotensin IV. Acts as a hepatocyte growth factor (HGF) mimetic and crosses the blood-brain barrier. Binds to and activates the c-Met receptor, promoting synaptogenesis, dendritic arborization, and neuronal repair. Reported to be more potent than BDNF in some in vitro synaptogenesis assays.
Half-Life
Limited human data — preclinical pharmacokinetic studies only
Route
oral
Frequency
Once daily (oral, community-derived)

Clinical Dosing

8-45 mgonce daily (oral, community-derived)

Not FDA-approved. Long-term safety, particularly regarding potential tumorigenic effects from c-Met activation, has not been established in humans. Human data is limited to anecdotal reports.

No established human clinical dose range. All human dosing is community-derived, extrapolated from rodent studies. Not validated by clinical trials.

Regulatory Status

FDA Category
Previously placed in Category 2 (Sept 2023). Removed from Category 2 following April 15, 2026 announcement. Scheduled for PCAC review before end of February 2027.
Reclassification
removed-from-cat2
Date Restricted
2023-09-29
Announced Return
2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Reference Range

Source: Community-derived from preclinical work — McCoy et al., J Pharmacol Exp Ther, 2013

DoseDurationDraw (10 mg vial in 2mL)Notes
8 mgMaintenance1.60 mL (160 units)Representative low-end community dose. No established human titration schedule.

Available Vial Sizes

10 mg

10 mg vial

20 mg

20 mg vial

Citations

  1. [1]Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. Journal of Pharmacology and Experimental Therapeutics, 344(1), 141-154. Link(Reviewed: 2026-04-16)